A5027217726- Cancer Immunotherapy and Biomarkers
- Drug-Induced Adverse Reactions
- Autoimmune Bullous Skin Diseases
- Chronic Lymphocytic Leukemia Research
- Pelvic and Acetabular Injuries
- Psoriasis: Treatment and Pathogenesis
- Sepsis Diagnosis and Treatment
- Hernia repair and management
- Poxvirus research and outbreaks
- Chronic Myeloid Leukemia Treatments
- Intensive Care Unit Cognitive Disorders
- CAR-T cell therapy research
- Hair Growth and Disorders
- Immunotherapy and Immune Responses
- Surgical site infection prevention
- Allergic Rhinitis and Sensitization
- Immune Response and Inflammation
- Pancreatitis Pathology and Treatment
- Nail Diseases and Treatments
- Urticaria and Related Conditions
- Dermatologic Treatments and Research
- Eosinophilic Disorders and Syndromes
- Lipid metabolism and disorders
- Clusterin in disease pathology
- Body Contouring and Surgery
Memorial Sloan Kettering Cancer Center
2023-2024
Robert Bosch Hospital
2021-2024
University of Tübingen
2009
Universitätsklinikum Tübingen
2008
Abstract Purpose The short-stitch technique for midline laparotomy closure has been shown to reduce hernia rates, but long stitches remain the standard of care and effect on short-term results is not well known. aim this study was compare two techniques, using an ultra-long-term absorbable elastic suture material. Methods Following elective laparotomy, 425 patients in 9 centres were randomised receive wound (USP 2-0 single thread, n = 215) or long-stitch 1 double loop, 210) with a...
Abstract Purpose: Immune-related cutaneous adverse events (ircAE) occur in ≥50% of patients treated with checkpoint inhibitors, but the underlying mechanisms for ircAEs are poorly understood. Experimental Design: Phenotyping/biomarker analyses were conducted 200 on inhibitors [139 and 61 without (control group)] to characterize their clinical presentation immunologic endotypes. Cytokines evaluated skin biopsies, tape strip extracts, plasma using real-time PCR Meso Scale Discovery multiplex...
Abstract Background Clinical trials have shown reduced incisional hernia rates 1 year after elective median laparotomy closure using a short-stitch technique. With development continuing beyond the first postoperative year, we aimed to compare hernias 3 years midline short or long stitches in patients from ESTOIH trial. Methods The trial was prospective, multicenter, parallel-group, double-blind, randomized-controlled study of primary closure. Patients were randomized fascia short-...
<p>Supplementary Figure S1. Flow summary of the standardized patient evaluation and specimen characterization in study.</p>
Background: Immune-related cutaneous adverse events (ircAEs) are frequent and may reduce quality of life consistent dosing. IL12/23 has been implicated in psoriasis, which is reminiscent the psoriasiform/lichenoid ircAE phenotype. We report use ustekinumab as a therapeutic option. Methods: Patients at Memorial Sloan Kettering Cancer Center, New York, who received immune checkpoint inhibitors were treated with or had keywords "ustekinumab" "Stelara" their clinical notes between 1 March 2017...
Abstract Background: Eosinophil-related cutaneous adverse events (ercAEs) are common toxicities of PI3K inhibitors, antibody drug conjugates (ADCs), checkpoint inhibitors (CPIs), and targeted cancer therapies. While systemic corticosteroids effective, their use is limited by additional high recurrence. Benralizumab an anti-IL-5Rα monoclonal that induces eosinophil depletion via antibody-dependent cellular cytotoxicity, FDA-approved for severe eosinophilic asthma but has not been studied...
<p>Supplementary Figure S4. Levels of pro-inflammatory mediators, chemokines, and alarmins in the skin tape strip (STS) plasma samples patients with cancer experiencing checkpoint inhibitor induced immune-related cutaneous adverse events (ircAEs).</p>
<p>Supplementary Figure S6. Representative clinical images and accompanying pie charts of the response eczema to dupilumab, pruritus omalizumab, maculopapular rash (MPR) systemic steroids, MPR/pruritus benralizumab, psoriasis ustekinumab.</p>
<p>Supplementary Figure S2. Peripheral blood differential cell counts assessment of patients with cancer experiencing checkpoint inhibitor induced immune-related cutaneous adverse events (ircAE).</p>
<p>Supplementary Figure S1. Flow summary of the standardized patient evaluation and specimen characterization in study.</p>
<p>Supplementary Figure S3. Serum IgE levels in patients with cancer experiencing checkpoint inhibitor induced immune-related cutaneous adverse events (ircAE).</p>
<p>Supplementary Figure S4. Levels of pro-inflammatory mediators, chemokines, and alarmins in the skin tape strip (STS) plasma samples patients with cancer experiencing checkpoint inhibitor induced immune-related cutaneous adverse events (ircAEs).</p>
<p>Supplementary Figure S6. Representative clinical images and accompanying pie charts of the response eczema to dupilumab, pruritus omalizumab, maculopapular rash (MPR) systemic steroids, MPR/pruritus benralizumab, psoriasis ustekinumab.</p>
<p>Supplementary Figure S7. Graphic representation of inflammatory pathways activated by checkpoint inhibitor (CPI) therapy in selected immune-related cutaneous adverse events (ircAEs) and associated targets for cytokine-directed therapies.</p>
<div>AbstractPurpose:<p>Immune-related cutaneous adverse events (ircAE) occur in ≥50% of patients treated with checkpoint inhibitors, but the underlying mechanisms for ircAEs are poorly understood.</p>Experimental Design:<p>Phenotyping/biomarker analyses were conducted 200 on inhibitors [139 and 61 without (control group)] to characterize their clinical presentation immunologic endotypes. Cytokines evaluated skin biopsies, tape strip extracts, plasma using real-time...
<p>Supplementary Figure S5. Treatment responses of patients with immune-related cutaneous adverse events (ircAEs; Cohort 1).</p>
<div>AbstractPurpose:<p>Immune-related cutaneous adverse events (ircAE) occur in ≥50% of patients treated with checkpoint inhibitors, but the underlying mechanisms for ircAEs are poorly understood.</p>Experimental Design:<p>Phenotyping/biomarker analyses were conducted 200 on inhibitors [139 and 61 without (control group)] to characterize their clinical presentation immunologic endotypes. Cytokines evaluated skin biopsies, tape strip extracts, plasma using real-time...